Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Nanogen to Host Third Quarter Conference Call on November 12, 2007

Abstract:
Nanogen, Inc. (Nasdaq:NGEN), developer of advanced diagnostic products, will host a conference call on Monday, November 12, 2007 at 4:30 p.m. Eastern (1:30 p.m. Pacific) to discuss 2007 third quarter financial results. The financial results press release will be issued at market opening on November 12, 2007. Interested investors and others may participate in the conference call by dialing 800.237.9752 for US/Canada participants and 617.847.8706 for international participants. The conference ID will be 99468930.

Nanogen to Host Third Quarter Conference Call on November 12, 2007

San Diego, CA | Posted on November 11th, 2007

Audio of management's presentation will be available via live webcast on the investor relations section of Nanogen's corporate website at http://www.nanogen.com , and will be archived for one year. A digital recording of the call will also be available for 48 hours, beginning two hours after the completion of the conference call on November 12, and can be accessed via telephone at 888-286-8010 for US/Canada participants and 617-801-6888 for international participants. The conference ID, 83888365, will be required to listen to the playback.

####

About Nanogen, Inc.
Nanogenís advanced technologies provide researchers, clinicians and physicians worldwide with improved methods and tools to predict, diagnose, and ultimately help treat disease. The company's products include real-time PCR reagents, the NanoChipģ electronic microarray platform and a line of rapid, point-of-care diagnostic tests. Nanogenís ten years of pioneering research involving nanotechnology holds the promise of miniaturization and continues to be supported for its potential for diagnostic and biodefense applications.

Nanogen Forward-Looking Statement

This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether the patents owned by Nanogen offer any protection against competitors with competing technologies, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogenís Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.

For more information, please click here

Contacts:
Nanogen, Inc.
Robert Saltmarsh, Chief Financial Officer, 858-410-4600
or
Kelly Gann, Marketing Communications, 858-410-4667

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics September 25th, 2018

Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics September 25th, 2018

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) September 25th, 2018

Viral RNA sensing: Optical detection of picomolar concentrations of RNA using switches in plasmonic chirality September 21st, 2018

Announcements

Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics September 25th, 2018

Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics September 25th, 2018

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) September 25th, 2018

Viral RNA sensing: Optical detection of picomolar concentrations of RNA using switches in plasmonic chirality September 21st, 2018

Financial Reports

Nanometrics to Announce Second Quarter Financial Results on July 31, 2018 July 12th, 2018

180 Degree Capital Corp. to Provide Live Remote Access to Its Annual Meeting of Shareholders on June 12, 2018 June 12th, 2018

Nanometrics Reports First Quarter 2018 Financial Results: Record Revenues, Gross Margin and Earnings; Outlook Strengthens for FY 2018 May 1st, 2018

Nanometrics to Announce First Quarter Financial Results on May 1, 2018 April 10th, 2018

Events/Classes

Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics September 25th, 2018

Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics September 25th, 2018

Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018 September 20th, 2018

Arrowhead Pharmaceuticals to Present at Upcoming September 2018 Conferences August 31st, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project